Searchable abstracts of presentations at key conferences in endocrinology

ea0049ep396 | Clinical case reports - Thyroid/Others | ECE2017

A case report of insulin autoimmune syndrome in a Caucasian

Jendrzejewski Jaroslaw , Obolonczyk Lukasz , Leczycka Martina , Sworczak Krzysztof

The Insulin Autoimmune Syndrome (IAS) also called Hirata’s disease consists of hypoglycemia, high insulin concentration and presence of anti-insulin antibodies. IAS is the third leading cause of spontaneous hypoglycemia among Japanese population. The syndrome is exceptionally rare among Caucasians, with <50 cases described in literature.In this report we showcase a 67 year-old female patient. She presented with paroxysmal sweating, daily fatigue...

ea0081p301 | Calcium and Bone | ECE2022

Assessment of the cardiovascular system in patients with primary hyperparathyroidism, including the role of aldosterone

Karwacka Izabela , Kaniuka-Jakubowska Sonia , Sworczak Krzysztof , Pisowodzka Izabela , Fijałkowski Marcin

Typical symptomatology of primary hyperparathyroidism (PNP) includes bone lesions and renal dysfunction in the form of recurrent nephrolithiasis but the symptoms of hypercalcemia may mimic other conditions, including cardiovascular diseases. The exact frequency of cardiac symptoms is not known. The study included 45 adult patients diagnosed with PNP, over 18 years of age, who were qualified for ptx. Laboratory tests included the determination of serum PTH, Ca, Pi and cardiac E...

ea0037ep666 | Pituitary: basic and neuroendocrinology | ECE2015

Dose interval injection extension and costs of lanreotide Autogel 120 mg used in routine acromegaly care in Poland: 2 years data from Lanro study

Orlewska Ewa , Kos-Kudla Beata , Sowinski Jerzy , Sworczak Krzysztof , Zgliczynski Wojciech

Objective: To determine the percentage of patients with acromegaly who received lanreotide Autogel 120 mg (ATG120) in extended duration interval and to evaluate the mean costs of ATG120 administered as part of routine care in Poland.Methods: National, multicentre, non-interventional, observational prospective study with 2-years’ time horizon. The study population consisted of adult acromegaly patients who received at least three injections of ATG120...

ea0035p223 | Clinical case reports Pituitary/Adrenal | ECE2014

Ineffectiveness of temozolomide in aggressive dopamine-agonist resistant prolactinoma and type 3 silent somatotropinoma

Kurowska Maria , Malicka Joanna , Tarach Jerzy S , Zielinski Grzegorz , Swiatkowska-Stodulska Renata , Sworczak Krzysztof

Introduction: Temozolomide (TMZ) can be administered as the last therapeutic option for aggressive pituitary tumors. Dopamine-agonist resistant prolactinomas are relatively frequent and remain a serious therapeutic problem. GH expressing atypical adenomas are rare and their positive response to TMZ is low. In a general opinion a lack of response to TMZ after three cycles predicts the treatment resistance.The aim of the study was presentation of two patie...

ea0035p672 | Growth hormone IGF axis basic | ECE2014

Demographic and clinical characteristics and treatment patterns of polish acromegalic patients switched to lanreotide AUTOGEL 120

Orlewska Ewa , Kos-Kudla Beata , Sowinski Jerzy , Sworczak Krzysztof , Zgliczynski Wojciech

Objective: The aim of the study was to examine characteristics and treatment patterns of Polish acromegalic patients.Methods: A retrospective database analysis was conducted. Adult acromegalic patients treated medically for ≥1 year including at least three injections of lanreotide AUTOGEL 120 were recruited in 36 centres between 29/10/2010 and 31/03/2012. Descriptive analysis was performed to describe demographic and clinical characteristics, treat...

ea0035p586 | Endocrine tumours and neoplasia | ECE2014

The anti-proliferative effect of anti-EGFR tyrosine kinase inhibitor in combination with mitotane on H295R adrenocortical cancer cells

Dworakowska Dorota , Dudka Dorota , Weistman Gregory , King Peter , Diaz-Cano Salvador , Korbonits Marta , Grossman Ashley B , Aylwin Simon , Schulte Klaus-Martin , Sworczak Krzysztof , Ng Tony

Introduction: Adrenocortical carcinoma (ACC) is a rare disease with a poor prognosis and limited therapeutic options. Mitotane is considered as a first-line therapy but only 30% of the patients showing an objective tumour response.Erlotinib and gefitinib (tyrosine kinase inhibitors – TKI) inhibit the epidermal growth factor receptor (EGFR), which is highly expressed and occasionally mutated in various cancers. EGFR expression was found to be a good ...

ea0070aep162 | Bone and Calcium | ECE2020

Oncogenic osteomalacia – from diagnosis to recovery in 7 days

Zalewska Ewa , Płoszaj-Neć Monika , Orzechowska-Pawiłojć Anna , Śledziński Maciej , Biernat Wojciech , Kaniuka-Jakubowska Sonia , Sworczak Krzysztof

Introduction: Oncogenic Osteomalacia (OO) is a rare paraneoplastic syndrome, resulting from fibroblast growth factor 23 overproduction. The rarity of the disease and nonspecific symptoms often cause delay in diagnosis by months, or even years. There are two cornerstones in the diagnostic process. The first concerns clinical identification, where awareness of this uncommon ailment combined with hypophosphatemia and clinical signs may be sufficient to identify OO. The second inv...

ea0056oc1.4 | Benign thyroid diseases | ECE2018

The impact of obligatory iodine prophylaxis on thyroid volume in schoolchildren

Trofimiuk-Muldner Malgorzata , Szybinski Zbigniew , Buziak-Bereza Monika , Sokolowski Grzegorz , Lewinski Andrzej , Zygmunt Arkadiusz , Sworczak Krzysztof , Ruchala Marek , Bandurska-Stankiewicz Elzbieta , Golkowski Filip , Hubalewska-Dydejczyk Alicja

Poland was considered as a mild-to-moderate iodine deficiency area according to results of a nation-wide survey conducted in early 1990-ties. The obligatory iodine prophylaxis program based on iodization of house-hold salt (30 mg of iodide/1 kg of salt) was therefore introduced in 1997.The aim of the study was to assess the real impact of the Polish iodine prophylaxis model on thyroid volume in schoolchildren.Material and methods: ...

ea0034p182 | Neoplasia, cancer and late effects | SFEBES2014

Pre-clinical assessment of the impact of Erlotinib on adrenocortical cancer cells proliferation

Dworakowska Dorota , Dudka Dorota , Weitsman Gregory , King Peter , Katugampola Harshini , Korbonits Marta , Schulte Klaus-Martin , Diaz-Cano Salvador , McGregor Alan , Grossman Ashley B , Aylwin Simon , Sworczak Krzysztof , Ng Tony

Introduction: Adrenocortical carcinoma (ACC) has a poor prognosis and limited therapeutic options. The epidermal growth factor receptor (EGFR) expression was found to be a good discriminator between malignant and benign adrenal tumours, but was mutated only in 3–10% of ACC cases.Aim: The aim of this study was to assess the effect of inhibition of EGFR with targeted therapies, i.e. Erlotinib (with and without EGF stimulation) on ACC cell proliferatio...

ea0073aep151 | Calcium and Bone | ECE2021

Phosphaturic mesenchymal tumour – diagnostic and therapeutic challenges

Zalewska Ewa , Monika Ploszaj-Neć , Bartosz Baścik , Szarmach Arkadiusz , Samson Lucjan , Piotr Łuczkiewicz , Katarzyna Goląbek-Dropiewska , Chmiel Joanna , Kardel-Reszkiewicz Ewelina , Kaniuka-Jakubowska Sonia , Sworczak Krzysztof

IntroductionTumour-induced osteomalacia (TIO) is a rare paraneoplastic syndrome caused mainly by a phosphaturic mesenchymal tumour (PMT) as a consequence of fibroblast growth factor 23 (FGF23) overproduction. The manifestation of TIO is mostly musculoskeletal. Locating the PMT is usually challenging and a successful surgical resection of the tumour leads to complete recovery.Case presentationA 42-year-old, Ca...